Table 1 Baseline characteristics of patients with axial spondyloarthritis from the PROOF and GESPIC cohorts
From: Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance
Parameter at baseline | PROOF (n = 1553) | GESPIC (n = 458) |
|---|---|---|
Age, years, mean (SD) | 34.7 (10.5) | 35.7 (10.3) |
Male sex, n (%) | 983 (63.3) | 243 (53.1) |
Duration of symptoms, years, mean (SD) | 4.7 (6.8) | 4.0 (2.7) |
HLA-B27 positive, n (%) | 836 (64.6) | 359 (78.4) |
CRP, mg/l, mean (SD) | 15.6 (23.0) | 11.5 (18.2) |
ASDAS-CRP, mean (SD) | 2.9 (1.1) | 2.6 (1.0) |
BASDAI, 0–10, mean (SD) | 4.5 (2.3) | 3.9 (2.1) |
BASFI, 0–10, mean (SD) | 3.3 (2.5) | 2.8 (2.3) |
Peripheral arthritis, n (%) | 503 (32.4) | 65 (14.2) |
Uveitis, n (%) | 151 (9.7) | 79 (17.3) |
Psoriasis, n (%) | 106 (6.8) | 49 (10.7) |
IBD, n (%) | 40 (2.6) | 12 (2.6) |
Family history of SpA, n (%) | 291 (18.7) | 147 (32.1) |
Treatment with NSAIDs, n (%) | 1204 (77.5) | 305 (66.6) |
Treatment with csDMARDs, n (%) | 539 (34.7) | 107 (23.4) |
Treatment with systemic steroids, n (%) | 119 (7.7) | 40 (8.7) |
Treatment with a TNF inhibitor, n (%) | 234 (15.1) | 11 (2.4) |